Compound ID | 1319
Class: Aminoacyl-tRNA synthetase inhibitor (tryptophanyl-tRNA synthetase [TrpS] inhibitor)
| Spectrum of activity: | Gram-positive |
| Details of activity: | Indolmycin is bacteriostatic and demonstrates good activity against MSSA (methicillin-susceptible Staphylococcus aureus), MRSA (methicillin-resistant S. aureus) and VISA (vancomycin-intermediate S. aureus), including strains resistant to mupirocin or fusidic acid. |
| Institute where first reported: | Chas. Pfizer & Co., Inc., Groton, Connecticut |
| Year first mentioned: | 1980 |
| Highest developmental phase: | Preclinical |
| Development status: | Active |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/135417159 |
| Guide to Pharmacology: | indolmycin |
| Citations: |
|